Saturday 17 October 2026
Export LXEO’s income statement to Excel — free account
Lexeo Therapeutics, Inc.
LXEO Healthcare Biotechnology
Lexeo Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $654,000.00. In the quarter to June 2026, EPS grew 50.0%, free cash flow grew 35.6% and total debt fell 83.5%, each against the same quarter a year earlier.
2.64
0.12
−4.35%
Follow LXEO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | — | — |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (4.19) | 18.12 | 10.97 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | (1.17) | (1.17) | (1.17) |
P/B ratio |
— | — | — | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
— | — | — | 0.19 | 0.19 | 0.19 |
EV/Operating CF |
— | — | — | 0.22 | 0.22 | 0.22 |
EV/FCF |
— | — | — | 0.22 | 0.22 | 0.22 |
Quick Ratio |
10.81 | 5.32 | 7.05 | 5.39 | 18.24 | 42.10 |
Current Ratio |
11.21 | 5.52 | 7.21 | 5.58 | 18.35 | 42.15 |
Net Debt/EBITDA |
1.67 | 1.14 | 1.76 | 1.25 | 2.68 | 5.75 |
Debt/Assets |
0.12% | 0.56% | 0.89% | 1.70% | 0.00% | 10.23% |
Debt/Equity |
0.00 | 0.01 | 0.01 | (0.01) | 0.00 | 0.12 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 |
Operating CF/Net income |
0.99 | 0.83 | 0.90 | 0.92 | 0.87 | 0.61 |
Capex/Depreciation |
(1.05) | (1.71) | (0.61) | (7.51) | 0.00 | — |
Interest Coverage |
(1,150.07) | (772.01) | (334.21) | (664.93) | (6,662.74) | (62.33) |
| (55.00%) | (85.37%) | (22,855.08%) | 70.34% | 165.60% | 0.00% | |
| (48.10%) | (68.58%) | (56.06%) | (50.68%) | (60.89%) | 0.00% | |
ROIC |
(104.69%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(57.87%) | (94.28%) | (61.41%) | (88.88%) | (39.12%) | (17.95%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 7,517.13% | 2,722.88% | 832.94% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 1,835.02% | 432.06% | 151.88% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 272.32% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | (10.93) | (10.93) | (10.93) |
Graham Number |
— | — | — | 205.29 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (424.09%) | (424.09%) | (424.09%) |
Free Cash Flow Yield |
— | — | — | (384.40%) | (384.40%) | (384.40%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.40 | 0.06 | 0.02 |
Operating CF per Share |
(1.84) | (2.55) | (11.11) | (33.47) | (1.66) | (0.12) |
Capex per Share |
(0.01) | (0.02) | (0.03) | (0.55) | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.84) | (2.57) | (11.14) | (34.03) | (1.66) | (0.12) |
Cash per Share |
3.39 | 3.82 | 22.69 | 47.44 | 5.10 | 1.10 |
Shareholders Equity per Share |
4.60 | 3.68 | 21.21 | (69.30) | 4.86 | 0.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.60 | 3.68 | 21.21 | (69.30) | 4.86 | 0.96 |
Free Cash Flow |
(98.96) | (81.63) | (59.66) | (55.46) | (44.18) | (3.13) |
Working Capital |
171.58 | 103.28 | 107.06 | 65.70 | 129.23 | 28.71 |
Capital Expenditures |
(0.40) | (0.48) | (0.16) | (0.90) | (0.19) | — |
Net Current Asset Value |
166.37 | 96.02 | 98.02 | (129.99) | 129.23 | 25.70 |
EV/EBIT |
— | — | — | 0.19 | 0.19 | 0.19 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 1.38 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||
Depreciation/Fixed assets |
0.33 | 0.27 | 0.26 | 0.12 | 0.08 | — |
Cash ROIC |
(23.08%) | (34.13%) | (25.25%) | 163.26% | (16.66%) | (5.39%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 83,372.54 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — |
Average Payables |
5.64 | 5.11 | 3.24 | 2.87 | 1.55 | — |
Average Assets |
207.82 | 143.37 | 118.44 | 116.97 | 83.14 | — |
Average Common Equity |
181.76 | 115.19 | 0.29 | (84.28) | (30.57) | — |
Columns are period end dates